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Abstract
Background: Nuclear receptors (NR) are a superfamily of ligand-activated transcription factors that control a range of
cellular processes. Persistent stimulation of some NR is a non-genotoxic mechanism of rodent liver cancer with unclear
relevance to humans. Here we report on a systematic analysis of new in vitro human NR activity data on 309 environmental
chemicals in relationship to their liver cancer-related chronic outcomes in rodents.
Results: The effects of 309 environmental chemicals on human constitutive androstane receptors (CAR/NR1I3), pregnane X
receptor (PXR/NR1I2), aryl hydrocarbon receptor (AhR), peroxisome proliferator-activated receptors (PPAR/NR1C), liver X
receptors (LXR/NR1H), retinoic X receptors (RXR/NR2B) and steroid receptors (SR/NR3) were determined using in vitro data.
Hepatic histopathology, observed in rodents after two years of chronic treatment for 171 of the 309 chemicals, was
summarized by a cancer lesion progression grade. Chemicals that caused proliferative liver lesions in both rat and mouse
were generally more active for the human receptors, relative to the compounds that only affected one rodent species, and
these changes were significant for PPAR (pv0.001), PXR (pv0.01) and CAR (pv0.05). Though most chemicals exhibited
receptor promiscuity, multivariate analysis clustered them into relatively few NR activity combinations. The human NR
activity pattern of chemicals weakly associated with the severity of rodent liver cancer lesion progression (pv0.05).
Conclusions: The rodent carcinogens had higher in vitro potency for human NR relative to non-carcinogens. Structurally
diverse chemicals with similar NR promiscuity patterns weakly associated with the severity of rodent liver cancer
progression. While these results do not prove the role of NR activation in human liver cancer, they do have implications for
nuclear receptor chemical biology and provide insights into putative toxicity pathways. More importantly, these findings
suggest the utility of in vitro assays for stratifying environmental contaminants based on a combination of human
bioactivity and rodent toxicity.
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Introduction
Nuclear receptors (NR) are a superfamily of ligand-activated
transcription factors that regulate a broad range of biological
processes including development, growth and homeostasis. NR
ligands include hormones [1] and lipids [2] but also xenobiotics
[3]. We are interested in NR because of their involvement in non-
genotoxic rodent liver cancer [4], a frequently observed effect in
chronic toxicity testing [5] and often a critical effect in risk
assessments of chemicals. Inferring the risk of chemical-induced
human liver cancer from rodent studies is difficult because the
underlying mechanisms are poorly understood. Persistent activa-
tion of NR is believed to be a possible mode of action [6,7]
operative in various pathways leading to cancer [8]. This raises a
public health concern because some environmental chemicals are
human NR activators and non-genotoxic rodent hepatocarcino-
gens including: pesticides [9,10], persistent chemicals [11], and
plastics ingredients [6]. In addition, there is very little available
biological information for thousands of environmental chemicals
so that new tools are needed to characterize their potential for
toxicity [12–15].
We are generating human in vitro NR assay data for hundreds of
environmental chemicals as a part of the ToxCast project [15].
Most of the Phase I ToxCast chemicals have undergone long-term
testing experiments in rodents and their chronic hepatic effects
have been curated and made publicly available in the Toxicology
Reference Database (ToxRefDB) [5]. Although small sets of
chemicals have been evaluated using selected NR in the past,
ToxCast is the largest public data set on chemicals, encompassing
concentration-dependent NR activity and chronic outcomes
including liver cancer. Hence, these data provide a unique
opportunity to investigate relationships between in vitro NR
activation and rodent hepatic effects.
Our objective is to stratify chemicals based on their putative
mode of action for human toxicity using data ranging from in vitro
molecular assays to in vivo rodent outcomes from ToxCast [16] and
other available resources. We have previously evaluated supervised
machine learning approaches [17] and used them to classify
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e14584chemicals by chronic toxicity outcomes using in vitro data. In this
analysis we used an unsupervised multivariate analysis of NR
activities and rodent liver lesions to investigate a potential mode of
action for non-genotoxic hepatocarcinogenesis.
Results
Nuclear Receptor Activity
Human NR activity for 309 environmental chemicals was
obtained from in vitro high-throughput screening (HTS) experi-
ments. Duplicates and triplicates for eight chemicals were included
for quality control purposes. HTS data were collected for 10 out of
the 48 human NR, selected based on availability of assays and
potential relevance to toxicology, including: members of the NR1,
NR2, NR3 and NR4 subfamilies. The aryl hydrocarbon receptor
(AhR) data was also included because of its potential role in
xenobiotic metabolism and non-genotoxic liver cancer [18]. A total
of 54 HTS assays were used to interrogate different facets ofreceptor
activation including: ligand binding in a cell-free system (Cell-free
HTS); reporter gene activation in HEK293 human cells [19] (Cell-
based HTS); multiplexed cis-activation and trans-activation assays
for transcription factors in human HepG2 cells [20] (Multiplexed
Transcription Reporter); and, multiplexed gene expression assays of
xenobiotic metabolizing enzymes regulated by specific NR in
primary human hepatocytes (Multiplexed Gene Expression). Data
for chemical-assay pairs were collected in concentration-response
format and either the AC50 concentration or the Lowest Effective
Concentration (LEC) were reported (additional details are provided
in supplementary methods, Text S1).
Aggregate Nuclear Receptor Activity
To summarize the activity of chemicalsacross theNRsuperfamily
we aggregated the ToxCast assays for genes and NR groups as
follows: retinoic X receptor-like (RXR; RXRa=b;N R 2 B ) ;p e r o x i -
some proliferator-activated receptor-like (PPAR; PPARa=d=c;
NR1C); constitutive androstane receptor (CAR; CAR1=2;
NR1I3=4); pregnane X receptor (PXR; NR1I2); liver X receptor-
like (LXR; LXRa=b, FXR; NR1H); and steroid receptor-like (SR;
ERa=b, ERRa=d, AR). These are shown visually in Figure 1(a). As
there were differences in the number and types of assays for each
group, aggregate activity was calculated as the average potency
across the assays measured by the AC50 or LEC (described in
Methods). This approach aggregated NR binding, activation,
agonism or antagonism results into a single assessment of activity.
The aggregate activity of each of 309 chemicals was calculated
across all assayed NR with the results visualized as the heatmap in
Figure 1(b). In this visualization, the rows represent the NR: RXR,
LXR, AhR, SR, PPAR, CAR and PXR. Columns correspond to
chemicals. The value of each cell is the aggregate scaled activity of
a chemical-NR pair, and the column intensities signify the
aggregate NR activity profile for each chemical (see Methods).
The intensity of the colors signifies the degree of activity, where
gray is inactive, yellow is the least active and red the most active.
The dendrogram to the left of the NR shows their functional
similarity across all 309 chemicals as two main groups. The first
group contains CAR and PXR, which are most similar in their
response across the chemicals, followed by AhR. The second
group includes PPAR, LXR, SR and RXR. The descending order
of similarity between: CAR, PXR, PPAR and SR is consistent with
receptor homology. CAR and PXR are members of NR1I (thyroid
hormone receptor-like), PPAR includes members of NR1C
(peroxisome proliferator-activator receptor), SR represents sub-
family NR3 (steroid receptor-like; estrogen and androgen). On the
other hand, the activities of RXR are not similar to other NR1
members and AhR belongs to the basic Helix-Loop-Helix/Per/
Arnt/Sim (bHLH-PAS) superfamily, which is distinct from NR.
Combinatorial Nuclear Receptor Activity
The chemicals were clustered by similarity of aggregate NR
activity into 7 putative groups (A-G) (described in Methods). The
average activity profile of the NR groups (NRG) are shown in the
columns of Figure 1(c). The rows signify the NR and their order
from top to bottom shows decreasing promiscuity and potency. The
letters and numbers in parentheses below each column are the
cluster designation and the number of chemicals in each cluster,
respectively. The colors signify the activity of a NR across the NRG:
red shows consistent activity and yellow inconsistent activity. For
example, the first column from the left of the heatmap shows NRG
A, which contains 41 chemicals that tend to activate AhR, PXR,
CAR, PPAR and in some cases also SR or LXR. These results
concisely describe how the 309 chemicals and 54 molecular assays
canbe summarized bydifferentgroupsofcombinatorialNRactivity.
The NRG correctly grouped 6 out of the 8 replicate chemicals
(Table 1). For the remaining two chemicals, the duplicate Dibutyl
phthalate samples had low NR activity and grouped closely in NRG
F and NRG G (these samples were separately sourced substances
from two different vendors). The triplicate Prosulfuron samples did
not group correctly and further analysis revealed this to likely be due
to degradation of the parent chemical prior to conducting the assays.
Comparing NR Activity with Cancer Lesion Progression
In vivo rat and mouse long-term histopathology outcomes for
chemicals were gathered from ToxRefDB [5] and organized by
severity of lesions progressing to cancer. Of the 309 ToxCast
chemicals, 232 were tested in 2-year chronic feeding studies in
both rat and mouse, and were characterized by liver histopathol-
ogy as follows: 61 caused no observable effects and 171 chemicals
caused a range of lesions of varying severity.
The 61 chemicals negative for any liver injury include:
Ethalfluralin, Fenamiphos, Fenthion, Isazofos, and Propetamphos
(NRG A); Cyazofamid and Fenhexamid (NRG B); Fenpyroximate,
Rotenone, Tebupirimfos (NRG C); and (51/61) in NRG D, E, F
and G (see Dataset S4). Since the absence of rat or mouse liver
toxicity is unusual after sustained treatment with a chemicals for
two years, it can indicate an insufficient treatment dose (among
other factors). When we reviewed the treatment protocols for these
61 chemicals we found that 7/10 chemicals in NRG A, B and C
may have been administered at insufficient doses to produce
hepatic effects. For example, Rotenone is a potent mitochondrial
inhibitor and commonly used as a pesticide. It can cause rodent
gastrointestinal injury at roughly 150 parts per million (ppm),
however, it was only tested at a maximum dose of 3.75 ppm in the
chronic study. Hence, we could not be certain about the absence
of liver toxicity for these 61 chemicals despite a lack of nuclear
receptor activity in a majority of 51 cases.
Lesion Progression and Nuclear Receptor Activities
We assumed that dose selection was not an issue for the 171
chemicals that produced at least some liver toxicity in chronic
rodent testing. Out of these 171 chemicals, 66 were mild
hepatotoxicants, 43 produced different grades of proliferative
lesions in rat and mouse, and 13 chemicals caused neoplastic
lesions in both species. The severity and concordance of hepatic
lesions across these 171 chemicals were clustered by similarity into
eight lesion progression groups shown in Figure 2(c) (see Methods).
TheaggregateNRactivitiesweresystematicallycompared acrossall
lesion progression groups (LPG) and visualized in Figure 3. The
rows in Figure 3 correspond to the eight lesion progression groups
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columns are the NR: AhR, CAR, PXR, PPAR, LXR, SR, RXR.
Each cell in the heatmap shows the ratio of the mean NR activities
of chemicals in a LPG compared to all other LPG. The statistical
significance of differences in mean NR activity was evaluated by
permutation and corrected for multiple testing (see Methods). AhR,
PPAR, SR and RXR showed 9% to 250% higher average activity
for chemicals in LPG I as compared to the other chemicals but only
PPAR showeda statisticallysignificant(pv0.001)increaseof150%.
For LPG II chemicals, all NR showed some increased activity
Figure 1. Nuclear receptor activity. Panel (a). Aggregation of 54 ToxCast assays for calculating seven nuclear receptor activities for AhR, CAR, PXR,
PPAR, LXR, SR and RXR. Abbreviations for different types of assays described in the text. Panel (b). Nuclear receptor activities (rows) of 309 chemicals
(columns). The color of each cell signifies degree of activity: gray means no activity, yellow is the least active and red the most active. The similarity
between 7 nuclear receptor activities shown as a dendrogram on the left. Panel (c). Chemical nuclear receptor activity groups shown in columns
labeled A-G and corresponding group size in parentheses. Colors represent relative activity of chemicals in each nuclear receptor activity group
across rows: gray is minimal, yellow is the least and red the most.
doi:10.1371/journal.pone.0014584.g001
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ABC D E F G
I Fludioxonil Diclofop-methyl Diethylhexyl Carbaryl Isoxaflutole 2,5-Pyridinedicarboxylic-
acid, dipropyl ester
Lactofen Diclofop-methyl phthalate Pymetrozine
Oxadiazon Diclofop-methyl Tepraloxydim
Imazalil
Malathion
Vinclozolin
II Bensulide Fentin Buprofezin Fenamidone Butafenacil Clodinafop-propargyl
Bensulide Fluazinam Fenarimol Diphenylamine Pyrithiobac-sodium
Bensulide Spirodiclofen Fluthiacet-methyl Fenoxycarb
Dithiopyr Piperonyl butoxide
MGK Pyraflufen-ethyl
Triflumizole Resmethrin
III Indoxacarb Bromoxynil Lindane Clofentezine Dicofol 3-Iodo-2-propynylbutyl-
carbamate
Iprodione Permethrin Cyproconazole Difenoconazole 3-Iodo-2-propynylbutyl-
carbamate
Linuron Prochloraz Nitrapyrin Dazomet
Propiconazole Propyzamide Fenoxaprop-ethyl
Thiazopyr Fenoxaprop-ethyl
Folpet
Quizalofop-ethyl
Thiamethoxam
IV Isoxaben Cinmethylin Hexythiazox Benfluralin Maneb 2-Phenylphenol
Methidathion Benomyl Primisulfuron- Acephate
Triadimefon Bifenazate Propoxur Amitraz
Triadimenol Bromacil Terbacil Bentazone
Tribufos Fenitrothion Cloprop
Norflurazon Daminozide
Thiophanate-methyl Dimethoate
Triflusulfuron-methyl Thiodicarb
V Cyclanilide Tebufenpyrad Ametryn Acetochlor Dichlobenil Mevinphos
Dimethenamid Simazine
VI Tetraconazole Azoxystrobin Boscalid Oxasulfuron Clothianidin
Butachlor Propanil Sethoxydim thephon
Chlorpropham Pyrimethanil Tralkoxydim Famoxadone
Flufenacet Rimsulfuron
Pendimethalin Thiram
Quintozene Trichlorfon
VII Flutolanil Bisphenol A Carboxin 2,4-DB Acetamiprid
Oxyfluorfen Carfentrazone-ethyl Dichloran Butylate Asulam
Triticonazole d-cis,trans-Allethrin Diuron Chlorpyrifos-methyl Azamethiphos
Fipronil Clorophene Cymoxanil
Metalaxyl Fenbuconazole Hexazinone
Prallethrin Flufenpyr-ethyl Mesosulfuron-methyl
Prosulfuron Flumiclorac-pentyl Novaluron
Sulfentrazone Fluoxastrobin Prosulfuron
Trifloxystrobin Myclobutanil Thiacloprid
Prometon Thidiazuron
Prosulfuron
Tefluthrin
Nuclear Receptors in Cancer
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(pv0.05) increases in activity of 80% and 50%, respectively. There
were no statistically significant differences in NR activities for
chemicals that produced only mouse proliferative lesions, however,
the subset of mouse carcinogens showed a 30% increase in AhR
activity but a 30% decrease in PPAR activity. Chemicals that
produced only rat hepatic neoplasms had a 75% increase in PPAR
activity, 23% increase in CAR activity and 30% increase LXR
activity but none were statistically significant.
Lesion Progression and Nuclear Receptor Activity Groups
The comparison between the LPG and NRG between 171
chemicals is visualized in Figure 4(c). The rows in Figure 4(c) are the
eight lesion progression groups (LPG I, II, III, IV, V, VI, VII, VIII)
shown in Figure 4(b) and the columns are the seven NR activity
groups (NRG A, B, C, D, E, F, and G) shown in Figure 4(c). Each
circle represents chemicalsthat have similar human NR activity and
degree of rodent lesion progression.The size of eachcircle visualizes
the proportion of chemicals across the LPG (rows) and NRG
(columns), while the color signifies confidence in assignment of
chemicals to each group (see Methods).
We designate each joint group by concatenating the identifier
as: LPG-NRG, and interpret the first row of Figure 4(c), which
corresponds to LPG I. The first circle from the left represents
group I-A, which is formed by the intersection of 13 chemicals in
LPG I and 29 chemicals in NRG A. The three chemicals in I-A
(shown in the first row and first column of Table 1), fludioxonil,
lactofen and oxadiazon were consistently active with AhR, PXR
and CAR, but less frequently with PPAR, LXR and SR.
Oxadiazon is a herbicide with known human PXR activity [21].
Lactofen is a poly-phenyl herbicide with PPARa activity in mice
[22]. Similarly, I-B, the second circle from the left, is the
intersection of 13 chemicals in LPG I and 10 chemicals in NRG B.
Chemicals in I-B include diclofop-methyl (each of the three
replicates), imazalil, malathion and vinclozolin. These chemicals
were most consistently active with PPAR, but also showed some
activity with PXR, CAR, AhR and SR. Imazalil is an imidazole
fungicide that perturbs human genes regulated by AhR [23] and is
also a PXR activator [21]; malathion is an organophosphorus
pesticide with known SR activity [24]; vinclozolin, a dicarbox-
imide fungicide is also a known SR active [25]; and diclofop-
methyl has been shown to be PPAR [26] active in rats. Group I-D
only contains diethylhexylphthalate (DEHP), which is a key
plastics monomer, and has been shown to activate PPARa [27],
PXR [28], and CAR [29]. In group I-E we have carbaryl, which is
a carbamate insecticide with AhR [30] and SR [31] activity.
Lastly, chemicals in I-F and I-G had negligible NR activity, which
could suggest that they act through other pathways.
Chemicals in LPG II produced only putative pre-neoplastic liver
lesions in rat and mouse but there is limited prior knowledge about
their NR activities.
LPG III only contains mouse hepatocarcinogens predominantly
active with AhR, PXR and CAR, but some propensity for PPAR,
LXR and SR. In III-A, the dicarboximide fungicide, iprodione, has
been shown to activate AhR in human HepG2 cells [32]; linuron
activates AhR in mouse [33], CAR in rat [34], and the triazole
fungicide,propiconazole,activatesCAR,PXRand PPARa inmice
[35]. The four chemicals in III-D namely, permethrin, lindane,
prochloraz and propyzamide, are most consistently active for CAR,
followed by AhR and PXR. In hepatocytes, permethrin [36] and
lindane [37] induce expression of the CAR, AhR and PXR target
xenobiotic metabolizing enzymes (XME), CYP2B6, CYP1A1=2,
and CYP3A4, respectively. Prochloraz has only been observed to
activate CAR and AhR [37]. Chemicals in III-E have lesser overall
NR activity but are generally more active with AhR and to a lesser
degree with CAR, PXR and PPAR. One of the chemicals in III-D,
cyproconazole, has been shown to induce expression of a
cytochrome P-450 in the 2B subfamily (CYP2B10), an XME
regulated by CAR across different mouse strains [38], however, the
expression of CYP1A1=2 was not measured in this study.
The relationship between NR activation and cancer lesion
progression is visualized by the location and size of circles: when
the NR activity is greatest (NRG A), many of the chemicals are
rodent hepatocarcinogens (LPG I) or just mouse carcinogens (LPG
I-IV); and when NR activity is the least (NRG G), most of the
chemicals produce mild or no lesions (LPG VII, VIII). For
intermediate grades of NR activity (NRG B-F), the relationships
are more complex: PPAR, PXR and SR activators (NRG B)
produced stage (iii) lesions (neoplastic) in both species (LPG I, V);
most CAR and PXR (NRG D) activators produced stage (ii)
lesions but some were also hepatocarcinogens; AhR, CAR and
PXR activators (NRG E) were mostly mouse hepatocarcinogens.
More importantly, the association of LPG I through VIII with
NRG A through G, shown in Figure 4(c) is statistically significant
with a p-value of 0.013 using Fisher’s exact test. There is greater
than 95% confidence that the observations on human nuclear
receptor activity and rodent cancer lesion progression are not by
chance alone.
ABC D E F G
Triasulfuron
VIII Cyprodinil Dimethomorph Alachlor Acibenzolar-S-Methyl Emamectin benzoate 2,4-Dichlorophenoxy-
acetic acid (2,4-D)
Etoxazole S-Bioallethrin Picloram Icaridin Chlorsulfuron
Flumetralin Ethofumesate Thiabendazole Paclobutrazol Chlorsulfuron
Hexaconazole Flusilazole Penoxsulam Cyhalofop-butyl
Methoxyfenozide Fosthiazate Triclosan Dichlorprop
Phosalone Dichlorvos
Pyraclostrobin Mesotrione
Tebufenozide
Chemicals assigned to nuclear receptor groups (columns) and lesion progression groups (rows).
doi:10.1371/journal.pone.0014584.t001
Table 1. Cont.
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Chemical-induced activation of NR has been evaluated
previously using HTS [3,39,40] but ToxCast is the largest publicly
available data set in terms of chemicals (309), number and
diversity of NR activities (7), NR assays (54), and associated rodent
in vivo toxicity data in ToxRefDB [5]. By analyzing the data, we
show that these chemicals concurrently activate multiple members
of the NR superfamily (NRG) in combinations that have not been
possible to systematically describe before. Since the 309 chemicals
may not be a representative sample of all environmental pollutants
and because we did not measure all NR, it is difficult to say
Figure 2. Cancer lesion progression. Panel (a). Chronic liver toxicity represented on the basis of cancer lesion progression as three
histopathologic stages. Chronic toxicity testing results for each chemical across mouse and rat species are represented by six dimension lesion
progression vector. Panel (b). Unique lesion progression vectors for all 171 chemicals. Columns represent histopathologic stages, and rows are groups
of chemicals with unique combinations of lesions across the two species. Cell colors indicate presence (dark blue) or absence (light blue) of lesions.
Panel (c). Chemical lesion progression groups in rows I-VIII and corresponding group sizes in parentheses. The proportion of chemicals in lesion
progression groups producing lesions at a specific stage (column) are shown as color intensity of cells.
doi:10.1371/journal.pone.0014584.g002
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our findings were generally consistent with what is known about
the NR activities for some chemicals.
Histopathologic observations in the liver have been also been
organized by severity for acute [4] and chronic injury in the past.
In our analysis, we integrated diverse phenotypic observations of
disease symptoms progressing from adaptive changes to neoplastic
lesions. In addition, we also summarized cancer progression data
across rat and mouse to contrast subtle differences in the severity
of adverse chronic outcomes. While this simplified the computa-
tional analysis of phenotypic data, it also represents three possible
limitations. First, all stages of lesion progression may not have been
observed at the terminus of a chronic bioassay. Second, we did not
consider the impact of gender and developmental stages, which
can be quite important in chemical carcinogenesis. Third, we did
not use information about the concentration at which lesions were
observed. This may be especially problematic for chemicals that
are dose limited (e.g. acetylcholinesterase inhibitors, many of
which are in the current data set), so that doses that might lead to
liver toxicity are never reached.
Finding robust relationships in real datasets is difficult because
measurements can be noisy or irrelevant, and observations can be
uninformative. While our analysis is not immune from these issues
we tried to mitigate their influence in two main ways. First, we
combined data on disparate molecular assays into an aggregate
measure of NR activity. The accuracy of this aggregate activity
can be demonstrated by the correct categorization of most
replicate chemicals into the same NRG (see Table 1.), despite
differences in NR assay profiles. Second, we grouped sparse
observations on histopathologic effects into three stages of lesion
severity in hepatocarcinogenesis. By independently organizing the
observations at these disparate biological scales, we found coherent
bioactivity profiles in relation to pathologic states.
Our findings have three main implications for toxicity testing.
First, it may be important to screen chemicals for multiple NR
activities for assessing the hazard of non-genotoxic liver cancer.
Second, the visualization inFigure 4 suggests a possible approachfor
interpreting disparate NRassays inthe contextofrodentliver cancer
severity, and also shows the uncertainties in using these data for
chemical prioritization. Third, NR activation by environmental
chemicals may be more conserved between rodents and humans
than previously believed [42]. This is corroborated partly by
comparison with the literature and also by similarities between the
aggregate activities of nuclear receptors across chemicals, which
appear to recapitulate their evolutionary relationships (Figure 3(b)).
Such a gradual functional divergence in the NR superfamily is
consistent with protein evolution [43] but it may also lead to
conservation of NRactivities between rodents and humans. Relating
these responsestodivergent phenotypicoutcomes,however,requires
a deeper understanding of non-genotoxic pathways to cancer.
Chronic animal testing is infeasible for the many thousands of
chemicals in commerce, but it is currently the gold-standard for
estimating human cancer risk. The EPA ToxCast program is
systematicallyassessingthevalueofhigh-throughputtechnologiesfor
Figure 3. Nuclear receptor activity and cancer lesion progression. Visualizing the relationship between the aggregate nuclear receptor
activities across the lesion progression group as a heatmap. The rows of the heatmap signify the lesion progression groups I-VIII and the columns
show the aggregate nuclear receptor activities. The colors represent the ratio of the aggregate nuclear receptor activity between chemicals in a lesion
progression group compared to others: decreased activities are shown in blue, no changes are shown in white and increased activity is shown in red.
Statistically significant changes are shown with a yellow asterisk in the cell.
doi:10.1371/journal.pone.0014584.g003
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pathways leading to human diseases such as cancer. Our objective
was to develop a tool for efficiently stratifying thousands of
environmental chemicals based on their perturbation of events
leading to adverse outcomes. Here we focused on liver cancer
because it is frequently observed across the 309 ToxCast chemicals,
and on NR activity since it is a putative key event in rodent
carcinogenesis. Through a unique analysis of these data we found
thathuman NRactivity profiles for thechemicals stratifiedtheirliver
cancer lesion progression inrodents.Thisrelationshipbetween thein
vitro molecular assays to in vivo rodent outcomes identifies putative
mode of action, advances our understanding of nuclear receptor
interactions with environmental chemicals, and suggests approaches
for efficient tiered testing for environmental carcinogens.
Methods
Multiplexed Gene Expression in Human Primary
Hepatocytes
This is a collection of multiplexed gene expression assays
focused on Phase I and II xenobiotic metabolizing enzymes and
transporters. Human primary cell cultures were treated with
Figure 4. Relating nuclear receptor activity and cancer lesion progression. Panels 3(a) and (b) are taken from Panels 1(c) and 2(c),
respectively. Panel 3(c). Visualizing the relationship between lesion progression group I-VIII (rows) and nuclear receptor groups A-G (columns). The
proportion of chemicals in the intersection of lesion progression groups and nuclear receptor groups visualized by circle size. Confidence in chemical
assignments to groups represented by color intensity from blue (high) to gray (low). Labels on the far right (I-VIII) and bottom (A-G) identify lesion
progression group and nuclear receptor group, respectively. Bar plots on the far right and bottom indicate number of chemicals in each lesion
progression group and nuclear receptor group, respectively.
doi:10.1371/journal.pone.0014584.g004
Nuclear Receptors in Cancer
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Concentration- and time-response profiles of chemicals were
measured by the expression of key nuclear receptor target genes,
activities of CYP1A enzymes (EROD), and cell morphology.
Fourteen gene targets were monitored by quantitative nuclease
protection assay including: six representative cytochrome P-450
genes, four hepatic transporters, three Phase II conjugating
enzymes, and one endogenous metabolism gene involved in
cholesterol synthesis. The target genes associated with nuclear
receptor pathways are as follows: CYP1A1 and CYP1A2 with
AhR; ABCB1, ABCG2, CYP2B6, CYP2C9, CYP2C19 and
UGT1A1 with CAR; CYP3A4, GSTA2, SLCO1B1 and
SULT2A1 with PXR; HMGCS2 with PPARa; and ABCB11
with FXR. Assays were run in primary human hepatocyte cultures
by CellzDirect Invitrogen Inc. (Durham, NC), in collaboration
with EPA.
Multiplexed Transcription Reporter Assays
A multiple reporter transcription unit (MRTU) library consist-
ing of 48 transcription factor binding sites was transfected into the
HepG2 human liver hepatoma cell line [20]. In addition to the cis-
acting reporter genes (CIS), a modification of the approach was
used to generate a trans-system (TRANS) with a mammalian one-
hybrid assay consisting of an additional 25 MRTU library
reporting the activity of nuclear receptor super-family members.
Based on an initial cytotoxicity screen, the maximum tolerated
concentration (MTC) was derived as one-third the calculated IC50
or, if no IC50 was determined, the MTC was set to 100 mM.
Chemicals were then tested in the CIS and TRANS assays at
seven concentrations starting at the MTC and followed by three-
fold serial dilutions. These assays were performed by Attagene Inc.
(Morrisville NC) under contract to EPA.
Cell-free HTS Assays
These are a collection of biochemical assays measuring binding
constants and enzyme inhibition values. Chemicals were initially
screened at a single concentration in duplicate wells at a
concentration of 10 mM for cytochrome P-450 assays and
25 mM for all others. Chemicals that showed significant activity
were then run in concentration response format, from which an
AC50 value was extracted. For concentration response, 8
concentrations were tested in the ranges 0.00914-20 mM for
cytochrome P-450 assays and 0.0229-50 mM for other assays.
These assays were run by Caliper Life Sciences (Hanover, MD)
under contract to EPA. Short assay descriptions are available at:
http://www.caliperls.com/products/contract-research/in-vitro/.
Cell-based HTS Assays
These assays measure binding constants and enzyme inhibition
values for nuclear receptors. The targets include AR, ER, FXR,
LXR, PPARa, PPARd, PPARc, RXRa, RXRb and PXR. Each
of the nuclear receptor targets was measured in agonist mode.
Assays were run at the NIH Chemical Genomics Center
(Rockville, MD).
In vitro data
All data used in this analysis are publicly available from the
ToxCast website (www.epa.gov/toxcast). The analysis was con-
ducted using the R statistical language (www.r-project.org). For
each chemical yi, and assay aj combination we derived either the
AC50 (50% maximal activity concentration) or LEC (Lowest
Effective Concentration) in mM denoted as, cij. All chemicals are
provided in Dataset S3 and all assays are given in Dataset S1. The
procedure for evaluating the quality of cij are described in the
supplementary methods (Text S1) and all assay results are
provided in Dataset S2. In order to facilitate comparison across
the assays the cij were transformed by the formula, cij
0~log10
(max(c)){log10(cij) where cij
0 represents a the potency on an
ascending scale, and max(c) is the maximum concentration
(lowest potency) across the data set.
Aggregating assay results
The aggregate NR activity w, where w[fCAR,PXR,PPAR,
AhR,SR,RXRg, was calculated using assays aw. The aggregate
scaled NR activity score for each chemical x
w
i was calculated as the
average concentration value across the assays, scaled by the
maximum value across all chemicals using Equation 1.
x
w
i ~
1
nw
P
j[aw
cij
maxi[y
1
nw
P
j[aw
cij
0
@
1
A
ð1Þ
The number of assays in aw is given by nw. Hence, the complete
NR activity of each chemical was defined as a vector using
Equation 2.
xi~fxCAR
i ,xPXR
i ,xPPAR
i ,xAhR
i ,xSR
i ,xRXR
i ,xLXR
i gð 2Þ
The NR activities of all chemicals were expressed as a matrix X,
where the rows are chemicals (y) and columns are the NR
activities (w).
Lesion Progression in Hepatocarcinogenesis
In vivo rat and mouse long-term histopathology outcomes were
extracted for 171 chemicals from ToxRefDB and organized by
severity into three stages [5] including: (i) non-proliferative, (ii)
putative pre-neoplastic and (iii) neoplastic lesions. For each
chemical, the incidence of hepatic tissue lesions was summarized
across rat and mouse species as a 6-dimensional cancer lesion
progression vector (LPV), which is depicted in Figure 2(a). The
resulting 37 unique LPV are shown in Figure 2(b). These LPV
were clustered by similarity (described below) into eight lesion
progression groups (LPG). The LPG are visualized as a heatmap in
Figure 2(c) and denoted by uppercase Roman numerals. The
colors of each cell in this heatmap are proportional to the number
of chemicals in the LPG that induce a specific lesion type.
Statistical tests
In addition to the two-sided t-test, 106 permutations were
carried out to empirically estimate the significance (type-I error) of
reported univariate statistics. The p-values calculated in this way
were adjusted for multiple comparisons using the false discovery
rate [44] (FDR) correction. The statistical significance of
associations between NRG and LPG were evaluated using Fisher’s
exact test.
Clustering
Hierarchical clustering was carried out using the Euclidean
distance metric and Ward’s minimum variance method for
agglomeration. The LPV and the NR data sets were partitioned
using k-means [45] clustering for K~2 to K~50, the resulting
partitions r were analyzed using the silhouette method [46], and
Nuclear Receptors in Cancer
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width. This procedure was used to partition chemicals into groups
of NR activity, NRG~fA,B,C,D,E,F,Gg, and groups of cancer
lesion progression, LPG~fI,II,III,IV,V,VI,VII,VIIIg.
Cluster stability
The assignment of chemicals to NRG and LPG was evaluated
by a cluster stability score, which was calculated using a subspace
sampling approach [47]. A subspace, q, of the data was defined by
randomly selecting w
q assays and y
q chemicals, where w
q5w and
y
q5y. For the chemicals y
q, the aggregate scaled activities across
w
q were calculated using Equation 1 to create the subspace data
matrix Xq. The matrix Xq was analyzed by k-means clustering (see
above), and chemicals y
q were then assigned to subspace clusters
rq. The partitions in rq were matched with the partitions r (from
the complete data set) based on the maximum number of common
members. That is, r
q
l :rk when max(y
q
l
T
yk) and f
q
k is the
fraction of chemicals from r in rq. The subspace sampling was
conducted Nq~1000 times and the quality vk of the partition rk
was calculated as vk~
1
Nq
P
q f
q
k .
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